ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.38 Insider Own1.10% Shs Outstand162.48M Perf Week-2.71%
Market Cap4.34B Forward P/E50.72 EPS next Y0.53 Insider Trans-22.34% Shs Float161.50M Perf Month-6.47%
Income-61.70M PEG- EPS next Q0.01 Inst Own98.40% Short Float3.90% Perf Quarter15.86%
Sales1.20B P/S3.62 EPS this Y57.10% Inst Trans0.18% Short Ratio3.94 Perf Half Y9.62%
Book/sh6.62 P/B4.06 EPS next Y-34.80% ROA-3.10% Target Price31.75 Perf Year20.75%
Cash/sh3.27 P/C8.21 EPS next 5Y- ROE-5.60% 52W Range21.24 - 33.00 Perf YTD15.56%
Dividend- P/FCF30.86 EPS past 5Y26.30% ROI-2.90% 52W High-17.52% Beta0.77
Dividend %- Quick Ratio1.90 Sales past 5Y9.50% Gross Margin82.40% 52W Low28.15% ATR1.37
Employees2211 Current Ratio2.20 Sales Q/Q10.80% Oper. Margin-3.30% RSI (14)46.46 Volatility4.50% 4.92%
OptionableYes Debt/Eq0.27 EPS Q/Q-57.30% Profit Margin-5.10% Rel Volume0.41 Prev Close26.88
ShortableYes LT Debt/Eq0.27 EarningsApr 27 BMO Payout- Avg Volume1.60M Price27.22
Recom2.80 SMA20-3.59% SMA50-0.30% SMA2001.04% Volume92,096 Change1.26%
Apr-22-22Resumed Goldman Buy $35
Apr-20-22Initiated Goldman Buy $35
Jan-27-22Upgrade Cantor Fitzgerald Hold → Overweight $32
Dec-01-21Initiated Citigroup Neutral $22
Oct-07-21Upgrade Jefferies Hold → Buy $36
Sep-02-21Downgrade BofA Securities Neutral → Underperform $27
Oct-15-20Upgrade Mizuho Neutral → Buy $19 → $24
Jul-30-20Downgrade Goldman Neutral → Sell $19 → $15
Feb-14-20Reiterated H.C. Wainwright Neutral $26 → $25
Feb-14-20Downgrade JP Morgan Overweight → Neutral $21
Feb-14-20Downgrade BofA/Merrill Buy → Neutral $31 → $20
Feb-06-20Initiated Mizuho Neutral
Jan-31-20Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
May-13-22 02:29PM  
10:22AM  
10:16AM  
May-12-22 02:47PM  
01:16PM  
10:27AM  
09:02AM  
May-11-22 02:28PM  
02:12PM  
11:12AM  
11:10AM  
10:32AM  
10:07AM  
09:47AM  
09:36AM  
07:15AM  
May-10-22 02:36PM  
11:37AM  
11:12AM  
11:11AM  
11:04AM  
11:03AM  
10:48AM  
10:44AM  
10:30AM  
10:14AM  
May-09-22 11:15AM  
11:06AM  
10:04AM  
07:00AM  
May-06-22 04:15PM  
03:48PM  
03:38PM  
03:02PM  
01:23PM  
01:06PM  
12:38PM  
12:17PM  
12:16PM  
11:11AM  
11:01AM  
11:01AM  
10:55AM  
10:53AM  
10:37AM  
10:34AM  
10:09AM  
May-05-22 02:14PM  
11:55AM  
11:30AM  
11:21AM  
11:03AM  
10:54AM  
10:49AM  
10:44AM  
10:28AM  
09:48AM  
09:44AM  
09:44AM  
09:41AM  
May-04-22 11:42AM  
11:19AM  
10:59AM  
10:57AM  
10:54AM  
10:48AM  
10:04AM  
May-03-22 10:48AM  
10:33AM  
09:47AM  
09:41AM  
May-02-22 10:02AM  
08:31AM  
07:00AM  
Apr-29-22 12:18PM  
11:01AM  
10:45AM  
07:11AM  
06:59AM  
Apr-28-22 12:30PM  
Apr-27-22 05:48PM  
04:56PM  
12:37PM  
12:01PM  
11:51AM  
09:25AM  
07:00AM  
Apr-26-22 11:44AM  
Apr-25-22 12:11PM  
Apr-21-22 02:21PM  
Apr-20-22 04:00PM  
11:14AM  
Apr-19-22 01:32PM  
07:30AM  
Apr-07-22 07:00AM  
Apr-04-22 09:06AM  
Mar-28-22 01:33PM  
12:46PM  
Mar-23-22 10:42AM  
Mar-22-22 04:00PM  
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 10Option Exercise16.5525,000413,750257,306May 12 04:21 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 10Sale27.2225,000680,380232,306May 12 04:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 06Option Exercise16.55120,8472,000,0181,062,046May 06 05:04 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 06Sale27.8593,7472,611,313968,299May 06 05:04 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 05Option Exercise16.55329,1535,447,4821,194,709May 06 05:04 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 05Sale28.03253,5107,106,470941,199May 06 05:04 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 03Option Exercise16.5525,000413,750257,306May 03 04:57 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 03Sale28.6225,000715,415232,306May 03 04:57 PM
Cooke ShaneDirectorMay 02Option Exercise16.5510,000165,500100,478May 03 04:56 PM
Cooke ShaneDirectorMay 02Sale29.2310,000292,33090,478May 03 04:56 PM
Cooke ShaneDirectorApr 25Option Exercise16.5510,000165,500100,478Apr 27 04:29 PM
Cooke ShaneDirectorApr 25Sale27.8810,000278,84990,478Apr 27 04:29 PM
Jackson Blair CurtisEVP, Chief Operating OfficerApr 20Option Exercise16.5549,999827,483137,914Apr 22 04:18 PM
Jackson Blair CurtisEVP, Chief Operating OfficerApr 20Sale29.6149,9991,480,33587,915Apr 22 04:18 PM
Cooke ShaneDirectorApr 18Option Exercise16.5510,000165,500100,478Apr 19 04:26 PM
Cooke ShaneDirectorApr 18Sale28.8810,000288,75090,478Apr 19 04:26 PM
Cooke ShaneDirectorApr 11Option Exercise16.5510,000165,500100,478Apr 12 04:54 PM
Cooke ShaneDirectorApr 11Sale29.2610,000292,60190,478Apr 12 04:54 PM
Cooke ShaneDirectorApr 04Option Exercise16.5510,000165,500100,478Apr 05 08:45 PM
Cooke ShaneDirectorApr 04Sale28.1810,000281,84590,478Apr 05 08:45 PM
snyderman nancy lynn MDDirectorMar 04Buy23.4342710,0059,366Mar 08 04:13 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 23Sale24.7611,983296,65017,994Feb 24 05:34 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 18Sale25.172,30658,0429,496Feb 23 04:40 PM
Alva Emily PetersonDirectorAug 23Buy30.221,65049,8601,650Aug 24 08:48 PM
Brown Iain MichaelSVP, Chief Financial OfficerAug 19Option Exercise16.5540,000662,00082,980Aug 20 04:22 PM
Brown Iain MichaelSVP, Chief Financial OfficerAug 19Sale29.9940,0001,199,60042,980Aug 20 04:22 PM
MCKEON BRIAN PDirectorAug 02Buy26.4310,000264,26910,000Aug 04 04:46 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jul 29Option Exercise16.5514,000231,70088,597Jul 30 04:20 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jul 29Sale26.0014,000364,00074,597Jul 30 04:20 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jun 10Option Exercise16.5513,500223,42588,097Jun 11 04:38 PM
DIXON WENDY LDirectorJun 10Option Exercise18.2125,000455,25066,300Jun 11 04:37 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jun 10Sale25.0013,500337,50074,597Jun 11 04:38 PM
DIXON WENDY LDirectorJun 10Sale25.0025,000625,00041,300Jun 11 04:37 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 09Sale24.6088221,6970Jun 11 04:36 PM
ANSTICE DAVID WDirectorJun 07Option Exercise14.605,00073,00078,081Jun 08 06:44 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jun 07Option Exercise16.5513,500223,42588,097Jun 08 06:50 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jun 07Sale24.0013,500324,00074,597Jun 08 06:50 PM
ANSTICE DAVID WDirectorJun 07Sale24.005,000120,00073,081Jun 08 06:44 PM
Wysenski NancyDirectorMay 20Option Exercise0.006,10406,104May 21 04:41 PM
Wilson Frank AndersDirectorMay 20Option Exercise0.006,10406,104May 21 04:40 PM
snyderman nancy lynn MDDirectorMay 20Option Exercise0.006,10406,104May 21 04:38 PM
MITCHELL PAUL JDirectorMay 20Option Exercise0.006,104014,104May 21 04:37 PM
GAYNOR RICHARDDirectorMay 20Option Exercise0.006,10406,104May 21 04:35 PM
Cooke ShaneDirectorMay 20Option Exercise0.006,104090,976May 21 04:34 PM
DIXON WENDY LDirectorMay 20Option Exercise0.006,104042,704May 21 04:34 PM
ANSTICE DAVID WDirectorMay 20Option Exercise0.006,104074,485May 21 04:32 PM
BREYER ROBERT ADirectorMay 20Option Exercise0.006,104013,260May 21 04:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 18Option Exercise18.11150,0002,715,750942,040May 19 04:27 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 18Sale21.90150,0003,285,405792,040May 19 04:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Option Exercise18.1150,000905,250266,781May 19 04:26 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Sale22.0950,0001,104,650216,781May 19 04:26 PM